

To: **Indira IVF Hospital Pvt Ltd-Dehradun**  
Ashirwad Towers, Above Nexa Showroom Ram  
Vihar,  
Ballupur Road, Chowk, Chakarata Rd, Ballupur,  
Uttara Khand  
Dehradun - 248001  
Contact:  
**Report Of: Mrs. PAPLI SISODIA**  
Pt. Contact: 8171308844



Sample ID 2100119433  
Patient ID 1002187732  
Received on 10/12/2021 15:54  
Registered on 11/12/2021 14:56  
Reported on 15/12/2021 22:01  
Referred by **DR.REEMA SIRCAR**  
Sonography by **DR.RAGHAV BHATIA**

**EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT**

Patient Name: Mrs. PAPLI SISODIA Patient DOB: 03/08/1977

Ethnicity: Asian City: DEHRADUN Hospital ID: FDUKDC20

**Sample Type:** Serum

**Risk assessment:** Algorithm validated by SURUSS 2003, N.J Wald

**Method:** Time-resolved Fluoroimmunoassay

EVICScreen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the international guidelines for prenatal screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)

**RISK ASSESSMENT**

T21 (Down syndrome)	<b>1: 29605</b>	● Low Risk	
T18 (Edwards' syndrome)	<b>1: 100000</b>	● Low Risk	
T13 (Patau syndrome)	<b>1: 32058</b>	● Low Risk	

**MULTIPLE OF MEDIAN (MoM)**

Free β-hCG	0.64	●
AFP	2.29	●
PAPP-A	0.85	●
PLGF	1.09	●

**INTERPRETATION**

The First Trimester - Quadruple Screening for the given sample is found **SCREEN NEGATIVE**.

**SUGGESTIONS AND OTHER FINDINGS**

In view of increased Alpha-fetoprotein (AFP), detailed anomaly scan to assess for fetal abnormalities especially that of the spine, anterior abdominal wall, and kidneys.



**UK NEQAS**  
International Quality Expertise  
Lab Reg. No. 90968

*Pradip Kadam*

Verified by  
**Mr. Pradip Kadam**  
Incharge Biochemistry

*Suresh Bhanushali*

Verified by  
**Dr. Suresh Bhanushali**  
MD (Path), Consultant Pathologist

Patient name : Mrs. PAPLI SISODIA

Sample ID : 2100119433

PREGNANCY DETAILS

No. of fetuses : 1      EDD : 24/06/2022      Age at Term : 30.4 Years  
 GA is Based on : Ass. rep.      LMP Date : 18/09/2021      LMP Certainty : Regular  
 Smoking : None      Parity :      Height :      Weight : 60.60 Kg  
 FHR :

Previous pregnancy history

Down syndrome       Edwards' syndrome  
 Patau syndrome       NTD syndrome

Pre-eclampsia history

PE in previous pregnancy  
 Pat. mother had PE

Other findings

Insulin dependent diabetes  
 Chronic hypertension

Assisted Reproduction : Donor egg      Transfer Date : 04/10/2021      Extraction Date : 30/01/2021      Donor DOB : 15/06/1991

Note! Age at term is calculated from the Donor DOB

EDD: Estimated Due Date | GA: Gestation Age | LMP: Last Menstrual Period | FHR: Fetal Heart Rate | NTD: Neural Tube Defect | PE: Pre-eclampsia | DOB: Date of Birth

SPECIMEN DETAILS

Sample ID	: 2100119433	CRL	: 50.5 mm	Test Name	Conc.	Unit	Corr. Mom
Collection Date	: 08/12/2021	CRL2	:	Free-β-hCG	31.02	ng/mL	0.64
Scan Date	: 08/12/2021	BPD	:	AFP	20.07	U/mL	2.29
GA at Coll Date	: 11 Weeks 5 Days	BPD2	:	PAPP-A	2061.00	mU/L	0.85
GA at Scan Date	: 11 Weeks 5 Days	HC	:	PLGF	42.78	pg/mL	1.09
Received on	: 10/12/2021	HC2	:				

GA: Gestation Age | CRL: Crown Rump Length | BPD: Bi-parietal Diameter | HC: Head Circumference | free-β-hCG: free-Beta Human Chorionic Gonadotropin  
 NT: Nuchal Translucency | PAPP-A: Pregnancy-associated Plasma Protein-A

RISKS

<b>Disorder: Down Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:29605      Age risk: 1:926		
Cutoff 1:250      Risk type Risk At Term		
<b>Disorder: Edwards' Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000      Age risk: 1:8333		
Cutoff 1:100      Risk type Risk At Term		
<b>Disorder: Patau Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:32058      Age risk: 1:25021		
Cutoff 1:100      Risk type Risk At Term		

Patient name : Mrs. PAPLI SISODIA

Sample ID : 2100119433

## PRENATAL SCREENING BACKGROUND

Every pregnant woman carries a certain degree of risk that her fetus/baby may have certain chromosomal defect/ abnormalities. Diagnosis of these fetal chromosomal abnormalities requires confirmatory testing through analysis of amniocytes or Chorionic Villous Samples (CVS). However, amniocentesis and CVS procedures carry some degree of risk for miscarriage or other pregnancy complications (Tabor and Alfirevic, 2010). Therefore in routine practice, prenatal screening tests are offered to a pregnant woman to provide her a personalised risk for the most common chromosomal abnormalities (T21-Down syndrome, T18- Edwards' syndrome, T13- Patau syndrome) using her peripheral blood sample. Based on this risk assessment, if the risk is high or intermediate, you can take informed decision of opting for invasive procedure such as amniocentesis or CVS followed by confirmatory diagnostic test(s), as per discussion with your clinician.

### PRENATAL SCREENING TESTS ARE NOT CONFIRMATORY TESTS. THEY ARE LIKELIHOOD ASSESSMENT TESTS.

You may get your prenatal screening result as either of the following:-

#### High Risk

**High Risk or Screen Positive Result:** A High Risk Result does not mean that the pregnancy is affected with the condition. It means that the likelihood of the pregnancy having a condition is higher than the cut-off (Most commonly used cut-off is 1:250 and this represents the risk of pregnancy loss from confirmatory testing through CVS or amniocentesis).

#### Low Risk

**Low Risk or Screen Negative Result:** A Low Risk result does not mean that the pregnancy is not affected with a condition. It means that the likelihood of the pregnancy having a condition is lower than the cut-off.

#### Intermediate Risk

**Intermediate Risk result:** An intermediate Risk result means that the pregnancy has an equivocal or a borderline risk of being affected with a condition. In this case, you may want to choose a second stage screening modality like an Integrated Screening Test that is done between 16 to 20 weeks of pregnancy or a Non-invasive Prenatal Screening Test between 12 to 20 weeks of pregnancy before taking a decision on an invasive confirmatory testing. This will help you improve the sensitivity of the screening test keeping an invasive test a last option were you to come as a high risk in the second stage screening test.

## SIGNIFICANCE OF MULTIPLE OF MEDIANS (MoMs)

Prenatal Screening determines the likelihood of the pregnancy being affected with certain conditions by analysing levels of certain hormones. These hormones are Feto placental products (released by Fetus or placenta). Their levels not only indicate propensity of the fetus being affected with certain chromosomal conditions, they also provide indication of placental insufficiency that can potentially lead to pregnancy complications like Pre-Eclampsia or Intra-Uterine Growth Restriction. It is therefore important to take cognisance of the Reported MoMs alongside the Risk results.

For more information, visit our website at: [www.lilacinsights.com/faq-pns](http://www.lilacinsights.com/faq-pns)

## DISCLAIMERS

### Limitations of the Test:

As prenatal screening tests are not confirmatory diagnostic tests, the possibility of false positive or false negative results can not be denied. The results issued for this test does not eliminate the possibility that this pregnancy may be associated with other chromosomal or sub- chromosomal abnormalities, birth defects and other complications.

Nuchal Translucency is the most prominent marker in screening for Trisomy 13, 18, 21 in the first trimester and should be measured in accordance with the Fetal Medicine Foundation (UK) guidelines. Nuchal Translucency or Crown Rump Length measurement, if not performed as per FMF (UK) imaging guidelines may lead to erroneous risk assessments and Lilac Insights bears no responsibility for errors arising due to sonography measurements not performed as per these criteria defined by international bodies such as FMF (UK), ISUOG.

It is assumed that the details provided along with the sample are correct. The manner in which this information is used to guide patient care is the responsibility of the healthcare provider, including advising for the need for genetic counselling or additional diagnostic testing like amniocentesis or Chorionic Villus Sampling. Any diagnostic test should be interpreted in the context of all available clinical findings. As with any medical test, there is always a chance of failure or error in sample analysis though extensive measures are taken to avoid these errors.

### Note:

- Quality of the Down's Syndrome & ONTD screening program (Biochemical values, MoMs and Risk assessments) monitored by UKNEQAS on an ongoing basis.
- This interpretation assumes that patient and specimen details are accurate and correct.
- Lilac Insights does not bear responsibility for the Ultra sound measurements.
- This is a risk estimation test and not a diagnostic test. An increased risk result does not mean that the fetus is affected and a low risk result does not mean that the fetus is unaffected. Reported risks should be correlated and adjusted according to the absence/presence of sonographic markers observed in the anomaly/malformation scan.
- The above risk has been calculated based on Biochemistry values alone.
- It must be clearly understood that the results represent risk and not diagnostic outcomes. Increased risk does not mean that the baby is affected and further tests must be performed before a firm diagnosis can be made. A low risk result does not exclude the possibility of Down's Syndrome or other abnormalities, as the risk assessment does not detect all affected pregnancies.



UK NEQAS  
International Quality Expertise  
Lab Reg. No. 90968

END OF REPORT